Neuropsychological Tests: COWA and Animal Naming at Study Entry.

<p>Neuropsychological Tests: COWA and Animal Naming at Study Entry.</p

Neuropsychological Tests: COWA and Animal Naming at Day 7.

<p>Neuropsychological Tests: COWA and Animal Naming at Day 7.</p

Consort Flow Diagram.

<p>Consort Flow Diagram.</p

Neuropsychological Tests: TMT at Study Entry.

<p>Neuropsychological Tests: TMT at Study Entry.</p

Distribution of mTBI Symptoms Co-morbid with Balance Dysfunction: Entry to Study.

<p>Distribution of mTBI Symptoms Co-morbid with Balance Dysfunction: Entry to Study.</p

Neuropsychological tests: TMT at Day 7.

*<p>p<0.05 or **p<0.01 by z-test versus TMTA (23.7±7.8 seconds (S.D.)) or TMTB.</p

Treatment Effects: Day 7 Symptoms.

*<p>95% Confidence Interval.</p

Unresolved mTBI Symptom Patterns on Treatment Day 7.

<p>Unresolved mTBI Symptom Patterns on Treatment Day 7.</p

Study Group Characteristics.

†<p>include vehicle dimensions (74/81 participants) and IED distance.</p>‡<p>Greater variance reflects the random inclusion of the two oldest individuals in the study population.</p

Nurr1 +/− mice exhibit greater reduction of striatal TH-immunoreactivity following METH exposure.

<p>(A) METH injection reduced THir in +/+ and +/− mice following one time binge METH exposure (1X METH) and repeated binge METH exposure (2XMETH). Calibration = 2 mm. (B) Quantitative THir fiber density analysis indicated that binge METH treatment significantly reduces THir in striatum and 2XMETH induced a further reduction of the THir in both +/+ and +/− mice. There is a significant difference between saline and 1XMETH group (p<0.001, Two-way ANOVA) and between 1XMETH and 2XMETH group (p<0.001, Two-way ANOVA) in striatal THir. In addition, there is also a significant difference (p<0.001) between +/+ and +/− mice after 1XMETH injection.</p